AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab ...

(Alliance News) - AstraZeneca PLC on Monday said its lung cancer drug Imfinzi has been recommended for approval in the EU. The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab ...

London open The FTSE 100 is expected to open 45 points higher on Monday, having closed up 0.61% on Friday at 8,809.74.

AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered perioperatively in combination with neoadjuvant chemotherapy, ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer. Read more here.